326 related articles for article (PubMed ID: 25515709)
1. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.
Walia JS; Altaleb N; Bello A; Kruck C; LaFave MC; Varshney GK; Burgess SM; Chowdhury B; Hurlbut D; Hemming R; Kobinger GP; Triggs-Raine B
Mol Ther; 2015 Mar; 23(3):414-22. PubMed ID: 25515709
[TBL] [Abstract][Full Text] [Related]
2. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
[TBL] [Abstract][Full Text] [Related]
3. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.
Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS
Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088
[TBL] [Abstract][Full Text] [Related]
4. Intravenous administration of scAAV9-Hexb normalizes lifespan and prevents pathology in Sandhoff disease mice.
Niemir N; Rouvière L; Besse A; Vanier MT; Dmytrus J; Marais T; Astord S; Puech JP; Panasyuk G; Cooper JD; Barkats M; Caillaud C
Hum Mol Genet; 2018 Mar; 27(6):954-968. PubMed ID: 29325092
[TBL] [Abstract][Full Text] [Related]
5. FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice.
Ogawa Y; Sano T; Irisa M; Kodama T; Saito T; Furusawa E; Kaizu K; Yanagi Y; Tsukimura T; Togawa T; Yamanaka S; Itoh K; Sakuraba H; Oishi K
Sci Rep; 2017 Jan; 7():40518. PubMed ID: 28084424
[TBL] [Abstract][Full Text] [Related]
6. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.
Rockwell HE; McCurdy VJ; Eaton SC; Wilson DU; Johnson AK; Randle AN; Bradbury AM; Gray-Edwards HL; Baker HJ; Hudson JA; Cox NR; Sena-Esteves M; Seyfried TN; Martin DR
ASN Neuro; 2015; 7(2):. PubMed ID: 25873306
[TBL] [Abstract][Full Text] [Related]
7. Reversibility of neuropathology in Tay-Sachs-related diseases.
Cachón-González MB; Wang SZ; Ziegler R; Cheng SH; Cox TM
Hum Mol Genet; 2014 Feb; 23(3):730-48. PubMed ID: 24057669
[TBL] [Abstract][Full Text] [Related]
8. Metabolic correction in microglia derived from Sandhoff disease model mice.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
[TBL] [Abstract][Full Text] [Related]
9. The trigeminal retrograde transfer pathway in the treatment of neurodegeneration.
Kyrkanides S; Yang M; Tallents RH; Miller JN; Brouxhon SM; Olschowka JA
J Neuroimmunol; 2009 Apr; 209(1-2):139-42. PubMed ID: 19278737
[TBL] [Abstract][Full Text] [Related]
10. Brain endothelial specific gene therapy improves experimental Sandhoff disease.
Dogbevia G; Grasshoff H; Othman A; Penno A; Schwaninger M
J Cereb Blood Flow Metab; 2020 Jun; 40(6):1338-1350. PubMed ID: 31357902
[TBL] [Abstract][Full Text] [Related]
11. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
[TBL] [Abstract][Full Text] [Related]
12. Improvement of motor and behavioral activity in Sandhoff mice transplanted with human CD34+ cells transduced with a HexA/HexB expressing lentiviral vector.
Beegle J; Hendrix K; Maciel H; Nolta JA; Anderson JS
J Gene Med; 2020 Sep; 22(9):e3205. PubMed ID: 32335981
[TBL] [Abstract][Full Text] [Related]
13. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.
Yamaguchi A; Katsuyama K; Suzuki K; Kosaka K; Aoki I; Yamanaka S
J Mol Med (Berl); 2003 Mar; 81(3):185-93. PubMed ID: 12682727
[TBL] [Abstract][Full Text] [Related]
14. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Kuwahara J; Yamanaka S; Itoh K
J Neurochem; 2005 Mar; 92(6):1497-507. PubMed ID: 15748167
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis.
Matsuoka K; Tamura T; Tsuji D; Dohzono Y; Kitakaze K; Ohno K; Saito S; Sakuraba H; Itoh K
Mol Ther; 2011 Jun; 19(6):1017-24. PubMed ID: 21487393
[TBL] [Abstract][Full Text] [Related]
16. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model.
Woodley E; Osmon KJL; Thompson P; Richmond C; Chen Z; Gray SJ; Walia JS
Mol Ther Methods Clin Dev; 2019 Mar; 12():47-57. PubMed ID: 30534578
[TBL] [Abstract][Full Text] [Related]
19. Suppression of NK and CD8
White EJ; Trigatti BL; Igdoura SA
J Neuroimmunol; 2017 May; 306():55-67. PubMed ID: 28385189
[TBL] [Abstract][Full Text] [Related]
20. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.
Toro C; Zainab M; Tifft CJ
Neurosci Lett; 2021 Nov; 764():136195. PubMed ID: 34450229
[No Abstract] [Full Text] [Related]
[Next] [New Search]